biib122/dnl151 - SERP Analysis

https://www.alzforum.org/therapeutics/dnl151

https://pubmed.ncbi.nlm.nih.gov/36807624/

https://www.neurologylive.com/view/biogen-denali-terminate-phase-3-lighthouse-study-biib122-lrrk2-parkinson-disease

https://investors.biogen.com/news-releases/news-release-details/statement-biogen-provides-update-parkinsons-disease-clinical

https://www.globenewswire.com/news-release/2024/12/05/2992284/0/en/Denali-Therapeutics-Announces-First-Participant-Dosed-in-Phase-2a-Study-of-LRRK2-Inhibitor-BIIB122-in-LRRK2-Associated-Parkinson-s-Disease.html

https://clinicaltrials.gov/study/NCT05418673

https://www.denalitherapeutics.com/patient-community/parkinsons-disease

https://www.neurologylive.com/view/first-patient-treated-phase-2a-trial-investigational-biib122-lrrk2-associated-pd

https://www.prd-journal.com/article/S1353-8020(25)00381-5/fulltext

https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.29297

https://www.denalitherapeutics.com/pipeline

https://investors.biogen.com/news-releases/news-release-details/biogen-and-denali-therapeutics-announce-initiation-phase-3

https://clinicaltrials.gov/study/NCT05005338

https://denalitherapeutics.gcs-web.com/node/8141/pdf

https://www.mdsabstracts.org/abstract/lrrk2-inhibition-by-biib122-dnl151-in-participants-with-pathogenic-lrrk2-variants-and-parkinsons-disease-study-design-to-evaluate-safety-pharmacodynamics-and-pharmacokinetics/

https://synapse.patsnap.com/drug/1594ce1ce0f24b0c98ba7d16d0995e3b

https://www.mdsabstracts.org/abstract/lrrk2-inhibition-by-biib122-dnl151-demonstrates-robust-target-and-lysosomal-engagement-pharmacokinetics-pharmacodynamics-and-safety-in-phase-1-and-phase-1b-studies-in-healthy-and-parkinsons/

https://delta.larvol.com/Products/?ProductId=5ceabcf9-284a-470e-aa40-cddde23f598a

https://www.globenewswire.com/news-release/2022/05/31/2453199/0/en/Denali-Therapeutics-and-Biogen-Announce-Initiation-of-Phase-2b-Study-of-LRRK2-Inhibitor-in-Parkinson-s-Disease.html

https://www.withpower.com/trial/phase-2-parkinson-disease-3-2022-56f29

https://adisinsight.springer.com/drugs/800050951

https://www.biospace.com/press-releases/denali-therapeutics-announces-key-anticipated-2025-milestones-and-priorities-to-further-advance-its-therapeutics-portfolio-for-neurodegeneration-and-lysosomal-storage-diseases

https://ddrare.nibn.go.jp/cgi-bin/drug_who_e.cgi?query=BIIB122&disease_id=6

https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-drug-drug-interaction-study-of-biib122dnl151-in-healthy-volunteers/

https://www.clinicaltrialsarena.com/news/biogen-denali-trial-parkinsons/

https://www.clinicaltrialsregister.eu/ctr-search/trial/2022-000747-77/IT

https://pipelinereview.com/denali-therapeutics-announces-first-participant-dosed-in-phase-2a-study-of-lrrk2-inhibitor-biib122-in-lrrk2-associated-parkinsons-disease/

https://movementdisorders.onlinelibrary.wiley.com/doi/am-pdf/10.1002/mds.29297

https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02323367/

https://ftp.druganalyst.com/bio/biib122%20(dnl151)

https://parkinsonsnewstoday.com/news/biib122-dnl151-safely-lowers-lrrk2-activity-phase-1-trials/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9643380/

https://www.researchgate.net/publication/368643300_LRRK2_Inhibition_by_BIIB122_in_Healthy_Participants_and_Patients_with_Parkinson's_Disease

https://www.isrctn.com/pdf/77591825

https://synapse.patsnap.com/blog/denali-initiates-phase-2a-trial-for-lrrk2-inhibitor-in-parkinsons

https://www.itiger.com/news/2489237703

https://scienceofparkinsons.com/2021/05/27/denali-3/

https://www.science.org/doi/10.1126/scitranslmed.abj2658

https://www.nature.com/articles/s41421-023-00639-8

https://www.prd-journal.com/article/S1353-8020(25)00381-5/pdf

https://ctv.veeva.com/study/a-study-of-mass-balance-pharmacokinetics-metabolite-profile-and-metabolite-identification-of-biib

https://www.biospace.com/denali-therapeutics-announces-key-anticipated-2024-milestones-and-priorities-to-further-advance-its-therapeutics-portfolio-for-neurodegeneration-and-lysosomal-storage-diseases

https://pharmaphorum.com/news/biogen-pulls-plug-late-stage-parkinsons-trial

https://www.nature.com/articles/d41573-022-00121-2

https://www.biorxiv.org/content/10.1101/2023.09.07.556689v1.full.pdf

https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-biib122-for-patients-with-lrrk2-associated-parkinsons-disease/

https://pmlive.com/pharma_news/biogen_and_denali_dose_first_patients_with_lrrk2_inhibitor_in_parkinsons_disease_study_1456283/

https://drughunter.com/articles/more-lrrk2-on-target-toxicity

https://www.stocktitan.net/news/DNLI/denali-therapeutics-announces-first-participant-dosed-in-phase-2a-vbvy735h52lg.html

https://www.isrctn.com/ISRCTN77591825

https://parkinsonsnewstoday.com/news/phase-2b-3-trials-planned-oral-biib122-dnl151-slowing-parkinsons-progression/

https://www.rttnews.com/3495383/denali-doses-first-patient-in-beacon-trial-of-biib122-for-lrrk2-mutant-parkinson-s-disease.aspx?type=bdc

https://www.nasdaq.com/articles/denali-doses-first-patient-beacon-trial-biib122-lrrk2-mutant-parkinsons-disease

https://www.probechem.com/products_BIIB122.html

https://www.kxan.com/business/press-releases/globenewswire/9314217/denali-therapeutics-announces-first-participant-dosed-in-phase-2a-study-of-lrrk2-inhibitor-biib122-in-lrrk2-associated-parkinsons-disease

https://www.youtube.com/watch?v=QxeWthkme0w

https://www.marketscreener.com/quote/stock/DENALI-THERAPEUTICS-INC-40101989/news/Denali-Therapeutics-Announces-First-Participant-Dosed-in-Phase-2a-Study-of-LRRK2-Inhibitor-BIIB122-48532766/

https://www.nasdaq.com/articles/biogen-biib-denali-begin-mid-stage-study-on-parkinsons-drug

https://www.mountsinai.org/clinical-trials/safety-pharmacodynamic-effects-of-biib122-in-participants-with-lrrk2-associated-parkinsons-disease-lrrk2-pd

https://denalitherapeutics.gcs-web.com/node/7361/pdf

https://ctv.veeva.com/study/safety-and-pharmacodynamic-effects-of-biib122-in-participants-with-lrrk2-associated-parkinsons-dise

https://scienceofparkinsons.com/2017/12/23/denali/

https://www.fiercebiotech.com/biotech/anxious-actionable-data-sooner-2031-biogen-trims-denali-partnered-parkinsons-program

https://www.biogentriallink.com/en-us/home/conditions/parkinsons.html?searchCondition=parkinson's&recruitingStatus=recruitingOnly

https://www.biopharmadive.com/news/biogen-denali-parkinsons-late-stage-study-lrrk2/633176/